Proventus
Making Life Fairer
Help-
Working together to make a difference
Find Us Here
If you have experienced any adverse side effects from a medication or therapy -
Dalfampridine -
A potassium channel blocker -
Dalfampridine blocks these exposed channels, and helps the electrical signals to pass through areas of damage.
Side effects may occur
- Urinary tract infection.
- Insomnia.
- Dizziness.
- Headache.
- Nausea.
- Asthenia.
- Back pain.
- Balance disorder.
- Multiple Sclerosis relapse.
- Paresthesia.
- Nasopharyngitis.
- Constipation.
- Dyspepsia.
- Pharyngolaryngeal pain.
Adverse side effects may occur
- The risk of seizures increases with increasing Ampyra doses. Ampyra is contraindicated in patients with a prior history of seizure.
- Contraindicated in patients with moderate or severe renal impairment (CrClless-
than or equal to 50 mL/min); the risk of seizures in patients with mild renal impairment (CrCl 51- - 80 mL/min) is unknown, but Ampyra plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures; estimated CrCl should be known before initiating treatment with Ampyra.
Ampyra should not be taken with other forms of 4-
Urinary tract infections were reported more frequently as adverse reactions in patients receiving Ampyra 10 mg twice daily compared to placebo.
Dalframpadine -
The drug, a potassium channel blocker, was shown in clinical trials to improve walking speeds vs placebo. It is the first drug approved for this use, an FDA statement notes; currently approved MS drugs are indicated to decrease relapse rates or in some cases to prevent accumulation of disability.
Source -
A phase III study involving 301 people with both relapsing and progressive MS who
were treated for 14 weeks was reported in The Lancet in 2009. This showed a greater
proportion of people taking dalfampridine had a consistent improvement in walking
speed, compared to people taking placebo (34.8 percent v 8.3 percent) as measured
by the Timed 25-Foot Walk test. This improvement was maintained for the duration
of the study.
Prior to the recent work looking at improving mobility, the drug was studied as a possible treatment for fatigue and cognitive problems.
In 2003, the Cochrane Review, an independent organisation that reviews research, published a report covering six trials of dalfampridine as a treatment for various symptoms. Although there was no apparent effect on cognitive symptoms, 54% of participants reported some degree of improved muscle function, 9% reported improvements in walking and 9% also showed improvement on the EDSS scale, a standard measure of neurological disability.
Dalfampridine was licensed by the Federal Drug Administration (FDA), the American regulatory body, in January 2010. Dalfampridine is not currently licensed in the UK. In January 2010, dalfampridine was submitted for a licence application in Europe. A decision is not expected before 2011.
Difficulties with walking are among the most pervasive and debilitating problems faced by people with MS. Walking disability affects the ability to accomplish daily tasks and limits their independence. Because there are currently no therapies indicated to improve walking impairment in MS, clinicians are limited in their ability to address this aspect of the disease.
Dalampridine appears to help improve mobility of people with MS, however it does
not slow the progression of MS. It is a symptomatic therapy, rather than one that
is likely to alter the course of the condition.
Biogen Idec has announced the submission of a marketing authorization application (MAA) to the European Medicines Agency for dalfampridine prolonged release tablets, a novel oral therapy for the improvement of walking ability in adult patients with multiple sclerosis (MS). The company also has filed a New Drug Submission (NDS) to Health Canada. "Walking impairment has a significant impact on the lives of many people living with MS," said Alfred Sandrock, MD, PhD, Senior Vice President, Neurology Research and Development, Biogen Idec. “Dalfampridine tablets may offer a novel approach to address this debilitating aspect of the disease by improving the walking ability of MS patients. We look forward to working with regulators to make this therapy available to people with MS in Europe and Canada."
The MAA submission and Canadian NDS are based on a comprehensive development program
including results from two Phase III, randomised, double-
In the two Phase III clinical trials, a significantly greater portion (p<0.001) of dalfampridine treated patients had a consistent improvement in walking speed when compared to placebo (34.8 percent vs. 8.3 percent and 42.9 percent vs. 9.3 percent, respectively). The increased response rate of the dalfampridine group was observed across all types of MS included in the studies.
The dalfampridine treated subjects who had consistent improvement in the two studies experienced an average increase in walking speed of 25.2 percent and 24.7 percent compared to 4.7 percent and 7.7 percent, respectively, for the entire placebo group.
The majority of the study participants in these trials were using immunomodulatory drugs, including interferons, glatiramer acetate, and natalizumab; however the magnitude of improvement in walking ability was independent of concomitant therapy (happens at the same time as, or in connection with another).
- Goodman AD, et al. Sustained-
release oral fampridine in multiple sclerosis: a randomised, double- blind, controlled trial. Lancet. 2009;373(9665):732- 738. Abstract - ncbi.nlm.nih.gov/pubmed - Korenke AR, et al. Sustained-
release fampridine for symptomatic treatment of multiple sclerosis. Annals of Pharmacotherapy 2008;42(10):1458- 1465. Abstract - ncbi.nlm.nih.gov/pubmed - Solari A, et al. Aminopyridines for symptomatic treatment in multiple sclerosis.
Cochrane Database Systematic Review 2003;(2). Abstract -
ncbi.nlm.nih.gov/pubmed
Top of Page